Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies

Journal of Virology

Volumn 78, Issue 13, 2004, Pages 6938-6945

  Zhang, Hong ^a   Wang, Guangwen ^a   Li, Jian ^a   Nie, Yuchun ^a   Shi, Xuanling ^a   Lian, Gewei ^a   Wang, Wei ^a   Yin, Xiaolei ^a   Zhao, Yang ^a   Qu, Xiuxia ^a   Ding, Mingxiao ^a   Deng, Hongkui ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; LEUCINE; NEUTRALIZING ANTIBODY; PROLINE; SERINE; VIRUS GLYCOPROTEIN; VIRUS SPIKE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN STRUCTURE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFICACY; DRUG SPECIFICITY; EPITOPE MAPPING; GENETIC CONSERVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN S2 DOMAIN; PROTEIN STRUCTURE; PSEUDOVIRUS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS SPIKE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; EPITOPES; FEMALE; HUMANS; IMMUNIZATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RABBITS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 2942647919     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.13.6938-6945.2004     Document Type: Article

References (47)

1. Abraham, S., T. E. Kienzle, W. Lapps, and D. A. Brian. 1990. Deduced sequence of the bovine coronavirus spike protein and identification of the internal proteolytic cleavage site. Virology 176:296-301.
2. Barbato, G., E. Bianchi, P. Ingallinella, W. H. Hurni, M. D. Miller, G. Ciliberto, R. Cortese, R. Bazzo, J. W. Shiver, and A. Pessi. 2003. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 330:1101-1115.
3. Boireau, P., C. Cruciere, and J. Laporte. 1990. Nucleotide sequence of the glycoprotein S gene of bovine enteric coronavirus and comparison with the S proteins of two mouse hepatitis virus strains. J. Gen. Virol. 71:487-492.
4. Bosch, B. J., R. van der Zee, C. A. M. de Haan, and P. J. M. Rottier. 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77:8801-8811.
5. Collins, A. R., R. L. Knobler, H. Powell, and M. J. Buchmeier. 1982. Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell-cell fusion. Virology 119:358-371.
6. Daniel, C., M. Lacroix, and P. J. Talbot. 1994. Mapping of linear antigenic sites on the S glycoprotein of a neurotropic murine coronavirus with synthetic peptides: a combination of nine prediction algorithms fails to identify relevant epitopes and peptide immunogenicity is drastically influenced by the nature of the protein carrier. Virology 202:540-549.
7. Daniel, C., R. Anderson, M. J. Buchmeier, J. O. Fleming, W. J. M. Spaan, H. Wege, and P. J. Talbot. 1993. Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure. J. Virol. 67:1185-1194.
8. De Groot, A. S. 2003. How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past. Vaccine 21:4095-4104.
9. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. D. Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
10. Drosten, C., S. Gunther, W. Preiser, S. van der Werf, H. R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R. A. M. Fouchier, A. Berger, A. M. Burguiere, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J. C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vieth, H. D. Klenk, A. D. M. E. Osterhaus, H. Schmitz, and H. W. Doerr. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976.
11. Enserink, M. 2003. Infectious diseases. Singapore lab faulted in SARS case. Science 301:1824.
12. Frana, M. F., J. N. Behnke, L. S. Sturman, and K. V. Holmes. 1985. Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: host-dependent differences in proteolytic cleavage and cell fusion. J. Virol. 56:912-920.
13. Gallagher, T. M., and M. J. Buchmeier. 2001. Coronavirus spike proteins in viral entry and pathogenesis. Virology 279:1-4.
14. Kobayashi, M., A. Iida, Y. Ueda, and M. Hasegawa. 2003. Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J. Virol. 77:2607-2614.
15. Koo, M., M. Bendahmane, G. A. Lettieri, A. D. Paoletti, T. E. Lane, J. H. Fitchen, M. J. Buchmeier, and R. N. Beachy. 1999. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc. Natl. Acad. Sci. USA 96:7774-7779.
16. Koolen, M. J., M. A. J. Borst, M. C. Horzinek, and W. J. M. Spaan. 1990. Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection. J. Virol. 64:6270-6273.
17. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J. A. Comer, W. Lim, P. E. Rollin, S. F. Dowell, A. E. Ling, C. D. Humphrey, W. J. Shieh, J. Guarner, C. D. Paddock, P. Rota, B. Fields, J. DeRisi, J. Y. Yang, N. Cox, J. M. Hughes, J. W. LeDuc, W. J. Bellini, L. J. Anderson, and SARS Working Group. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:1953-1966.
18. Kubo, H., Y. K. Yamada, and F. Taguchi. 1994. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J. Virol. 68:5403-5410.
19. Kuiken, T., R. A. M. Fouchier, M. Schutten, G. F. Rimmelzwaan, G. van Amerongen, D. van Riel, J. D. Laman, T. de Jong, G. van Doornum, W. Lim, A. E. Ling, P. K. S. Chan, J. S. Tam, M. C. Zambon, R. Gopal, C. Drosten, S. van der Werf, N. Escriou, J. C. Manuguerra, K. Stöhr, J. S. M. Peiris, and A. D. M. E. Osterhaus. 2003. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362:263-270.
20. Lenstra, J. A., J. G. Kusters, G. Koch, and B. A. M. van der Zeijst. 1989. Antigenicity of the peplomer protein of infectious bronchitis virus. Mol. Immunol. 26:7-15.
21. Li, W., M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M. Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, H. Choe, and M. Farzan. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454.
22. Luytjes, W., D. Geerts, W. Posthumus, R. Meloen, and W. Spaan. 1989. Amino acid sequence of a conserved neutralizing epitope of murine coronaviruses. J. Virol. 63:1408-1412.
23. Luytjes, W., L. S. Sturman, P. J. Bredenbeek, J. Charite, B. A. M. van der Zeijst, M. C. Horzinek, and W. J. M. Spaan. 1987. Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site. Virology 161:479-487.
24. Marra, M. A., S. J. M. Jones, C. R. Astell, R. A. Holt, A. Brooks-Wilson, Y. S. N. Butterfield, J. Khattra, J. K. Asano, S. A. Barber, S. Y. Chan, A. Cloutier, S. M. Coughlin, D. Freeman, N. Girn, O. L. Griffith, S. R. Leach, M. Mayo, H. McDonald, S. B. Montgomery, P. K. Pandoh, A. S. Petrescu, A. G. Robertson, J. E. Schein, A. Siddiqui, D. E. Smailus, J. M. Stott, G. S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T. F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G. A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R. C. Brunham, M. Krajden, M. Petric, D. M. Skowronski, C. Upton, and R. L. Roper. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399-1404.
25. Moore, K. M., M. W. Jackwood, and D. A. Hilt. 1997. Identification of amino acids involved in a serotype and neutralization specific epitope within the s1 subunit of avian infectious bronchitis virus. Arch. Virol. 142:2249-2256.
26. Normile, D. 2004. Infectious diseases. Second lab accident fuels fears about SARS. Science 303:26.
27. Peiris, J. S. M., S. T. Lai, L. L. M. Poon, Y. Guan, L. Y. C. Yam, W. Lim, J. Nicholls, W. K. S. Yee, W. W. Yan, M. T. Cheung, V. C. C. Cheng, K. H. Chan, D. N. C. Tsang, R. W. H. Yung, T. K. Ng, K. Y. Yuen, and SARS Study Group. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325.
28. Phillips, J. J., M. M. Chua, G. F. Rail, and S. R. Weiss. 2002. Murine coronavirus spike glycoprotein mediates degree of viral spread, inflammation, and virus-induced immunopathology in the central nervous system. Virology 301:109-120.
29. Poignard, P., M. Moulard, E. Golez, V. Vivona, M. Franti, S. Venturini, M. Wang, P. W. H. I. Parren, and D. R. Burton. 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77:353-365.
30. Posthumus, W. P., J. A. Lenstra, W. M. Schaaper, A. P. van Nieuwstadt, L. Enjuanes, and R. H. Meloen. 1990. Analysis and simulation of a neutralizing epitope of transmissible gastroenteritis virus. J. Virol. 64:3304-3309.
31. Prentice, E., and M. R. Denison. 2001. The cell biology of coronavirus infection. Adv. Exp. Med. Biol. 494:609-614.
32. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100:4144-4149.
33. Rota, P. A., M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P. Icenogle, S. Peñaranda, B. Bankamp, K. Maher, M. H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J. L. DeRisi, Q. Chen, D. Wang, D. D. Erdman, T. C. T. Peret, C. Burns, T. G. Ksiazek, P. E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Günther, A. D. M. E. Osterhaus, C. Drosten, M. A. Pallansch, L. J. Anderson, and W. J. Bellini. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399.
34. Ruan, Y. J., C. L. Wei, A. L. Ee, V. B. Vega, H. Thoreau, S. Y. S. Thoe, J. M. Chia, P. Ng, K. P. Chiu, L. Lim, T. Zhang, K. P. Chan, L. E. O. Oon, M. L. Ng, S. Y. Leo, L. F. P. Ng, E. C. Ren, L. W. Stanton, P. M. Long, and E. T. Liu. 2003. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 361:1779-1785.
35. Siddell, S., H. Wege, and V. Ter Meulen. 1983. The biology of coronaviruses. J. Gen. Virol. 64:761-776.
36. Spaan, W. J. M., D. Cavanagh, and M. C. Horzinek. 1988. Coronaviruses: structure and genome expression. J. Gen. Virol. 69:2939-2952.
37. Spiga, O., A. Bernini, A. Ciutti, S. Chiellini, N. Menciassi, F. Finetti, V. Causarono, F. Anselmi, F. Prischi, and N. Niccolai. 2003. Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem. Biophys. Res. Commun. 310:78-83.
38. Sturman, L. S., C. S. Ricard, and K. V. Holmes. 1985. Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: activation of cell-fusing activity of virions by trypsin and separation of two different 90K cleavage fragments. J. Virol. 56:904-911.
39. Taguchi, F. 1995. The S2 subunit of the murine coronavirus spike protein is not involved in receptor binding. J. Virol. 69:7260-7263.
40. Takase-Yoden, S., T. Kikuchi, S. G. Siddell, and F. Taguchi. 1991. Localization of major neutralizing epitopes on the S1 polypeptide of the murine coronavirus peplomer glycoprotein. Virus Res. 18:99-107.
41. Talbot, P. J., A. A. Salmi, R. L. Knobler, and M. J. Buchmeier. 1984. Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): correlation with biological activities. Virology 132:250-260.
42. Talbot, P. J., and M. J. Buchmeier. 1985. Antigenic variation among murine coronaviruses: evidence for polymorphism on the peplomer glycoprotein, E2. Virus Res. 2:317-328.
43. Thiel, V., K. A. Ivanov, A. Putics, T. Hertzig, B. Schelle, S. Bayer, B. Weißbrich, E. J. Snijder, H. Rabenau, H. W. Doerr, A. E. Gorbalenya, and J. Ziebuhr. 2003. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84:2305-2315.
44. Vautherot, J. F., J. Laporte, and P. Boireau. 1992. Bovine coronavirus spike glycoprotein: localization of an immunodominant region at the amino-terminal end of S2. J. Gen. Virol. 73:3289-3294.
45. Vautherot, J. F., M. F. Madelaine, P. Boireau, and J. Laporte. 1992. Bovine coronavirus peplomer glycoproteins: detailed antigenic analyses of S1, S2 and HE. J. Gen. Virol. 73:1725-1737.
46. Wang, P., J. Chen, A. Zheng, Y. Nie, X. Shi, W. Wang, G. Wang, M. Luo, H. Liu, L. Tan, X. Song, Z. Wang, X. Yin, X. Qu, X. Wang, T. Qing, M. Ding, and H. Deng. 2004. Expression cloning of functional receptor used by SARS coronavirus. Biochem. Biophys. Res. Commun. 315:439-444.
47. Yu, M. W. N., J. K. Scott, A. Fournier, and P. J. Talbot. 2000. Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides. Virology 271:182-196.